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Abstract
Background: Asthma is a complex phenotype that is influenced by both genetic and environmental factors.
Genome-wide linkage and association studies have been performed to identify susceptibility genes for asthma.
These studies identified new genes and pathways implicated in this disease, many of which were previously
unknown.
Objective: To perform a large-scale genotyping study to identify asthma-susceptibility genes in the Japanese
population.
Methods: We performed a large-scale, three-stage association study on 288 atopic asthmatics and 1032 controls,
by using multiplex PCR-Invader assay methods at 82,935 single nucleotide polymorphisms (SNPs) (1st stage). SNPs
that were strongly associated with asthma were further genotyped in samples from asthmatic families (216
families, 762 members, 2nd stage), 541 independent patients, and 744 controls (3rd stage).
Results: SNPs located in the 5' region of PEX19 (rs2820421) were significantly associated with P < 0.05 through
the 1st to the 3rd stage analyses; however, the P values did not reach statistically significant levels (combined, P =
3.8 × 10-5; statistically significant levels with Bonferroni correction, P = 6.57 × 10-7). SNPs on HPCAL1 (rs3771140)
and on IL18R1 (rs3213733) were associated with asthma in the 1st and 2nd stage analyses, but the associations were
not observed in the 3rd stage analysis.
Conclusion: No association attained genome-wide significance, but several loci for possible association emerged.
Future studies are required to validate these results for the prevention and treatment of asthma.
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Findings
Asthma is the most common chronic disorder in children,
and asthma exacerbation is an important cause of child-
hood morbidity and hospitalization. Currently, approxi-
mately 300 million people worldwide have asthma, and
this disease claims the lives of 180,000 people every year
[1].
Asthma and atopy are complex phenotypes that are influ-
enced by both genetic and environmental factors. Twin
studies have supported the role of a strong genetic contri-
bution with a heritability of 0.71 [2], and asthma shows a
familial risk higher than that of many common diseases
such as stroke, epilepsy, and most types of cancer [3].
Atopy is characterized by increased levels of immunoglob-
ulin E (IgE) against common environmental allergens,
and is considered the strongest predisposing factor for
asthma. Majority of children with asthma develop specific
IgE against house dust mites, and dust mite allergy is
strongly associated with asthma [4,5], however, only a
small subset of subjects with dust mite allergy develops
asthma [6]. These data suggest that other factors are
involved in the development of asthma, and genome-
wide linkage and association studies have been used to
find novel asthma genes and their associated pathways
[7]. Using family and case-referent panels of European
populations and based on the genome-wide association
study conducted on asthma, Moffatt et al. identified that
the cis-acting single nucleotide polymorphisms (SNPs) in
ORMDL3 were associated with asthma [8], and the results
were replicated in independent populations [9].
In order to identify novel asthma susceptibility genes, we
performed a large-scale, 3-stage association study using
the Japanese population. No association attained
genome-wide significance, but several loci for possible
association emerged. Further studies are required to vali-
date these results in the future.
Subjects and genotyping results
The childhood asthmatics in the case-control study (1st
and 3rd stage analysis) were atopic asthmatic children
diagnosed by pediatricians on the basis of clinical exami-
nation. Probands of the asthmatic families (2nd stage)
were atopic asthmatic children who visited the Pediatric
Allergy Clinic of the University Hospital of Tsukuba. Two
hundred and sixteen families (762 members), provided
informed consent and participated in this study. The clin-
ical details of the families are shown in Table 1. The crite-
ria used for the diagnosis of asthma in case-control study
and families were the same, and have been previously
described [10]. The control group comprised 1032 adult
Japanese individuals from the general population (1st
stage) and 744 healthy adults (ages, 19–78 years, mean
46.2 years) with no history of any allergic disease (3rd
stage). Cases and controls as well as asthmatic families
were recruited from the mainland of Japan. This study was
approved by the Committee of Ethics of the University of
Tsukuba. The details of the study populations are shown
in Table 2.
Large-scale genotyping using 82,935 randomly selected
gene-based SNPs was carried out using the high-through-
put multiplex PCR-Invader assay method as described
previously [11]. The population frequency of asthma in
Japan was 0.065 [12], and the statistical power of the 1st
stage analysis was 0.93 and 0.44 at the alpha level of 0.001
and 0.000001, respectively if the relative risk for asthma
in those persons carrying a putative risk allele is 2 and the
high risk allele frequency is 0.3 compared with that in per-
sons without the allele. Therefore, our sample size may
not be enough to detect a low risk allele.
The SNPs genotyped in the 1st stage analysis were those
identified in the JSNP project [11]. There are 2 approaches
to the construction of SNP databases: one is genome-wide
screening, and the other is gene-based screening.
Although SNPs around genes are likely to be functional
SNPs, it should be noted that SNPs outside genes have
also been found to be associated with diseases.
In the present study, the distribution of allelic frequencies
was largely even, with an average minor allele frequency
of 24%. The SNPs with problematic genotyping in the 1st
stage were flagged, and we excluded these SNPs from the
analysis (n = 4683). Moreover, Hardy-Weinberg equilib-
rium was calculated using the χ2 test with 2 degrees of free-
dom on the basis of the observed and expected genotype
frequencies; SNPs with P  < 0.001 (n = 2160) were
excluded from the analysis. After the exclusions, 76,092
autosomal SNPs were available for analysis. The signifi-
cance of the differences in the allele frequencies in case-
control comparisons was determined by the χ2 test with 1
degree of freedom. The distribution of the observed P val-
ues was as follows: P < 0.0001, 20 SNPs (0.0263%); P <
0.001, 146 SNPs (0.192%); and P  < 0.01, 1111 SNPs
(1.46%). The genomic inflation factor of the study popu-
lation was calculated using the method described by Dev-
lin et al [13] and was found to be 1.13. A previous study
Table 1: Clinical details of the asthmatic families
No. of Families 216
No. of children 346
No. of affected children 315
Mean age (yeas ± SD) 10.9 ± 2.4
Male:Female ratio 1.8:1
Log(total IgE) (IU/ml ± SD) 2.8 ± 0.6
No. of parents 416
Mean age (yeas ± SD) 40.7 ± 7.5
Log(total IgE) (IU/ml ± SD) 2.0 ± 0.7BMC Research Notes 2009, 2:54 http://www.biomedcentral.com/1756-0500/2/54
Page 3 of 5
(page number not for citation purposes)
has reported that the inclusion of different proportions of
individuals from different regions of Japan in case and
control groups can lead to an exaggerated number of false-
positive results when the sample sizes are large, and it has
recommended the exclusion of subjects belonging to the
Ryukyu (southern island of Japan) cluster [14]. The
patients of the present study were from the Kanto and
Kinki regions, and the controls were from the Kinki region
alone. On the basis of the results of a previous simulation
study, we can state that the subjects from the Kanto region
are not genetically different from those from the Kinki
region [14]; moreover, we did not include cases or con-
trols from the Ryukyu island. However, we cannot exclude
the possibility that population stratification exists in our
case-control samples.
We used a cut-off P value of 0.002 (corrected P = 0.0036)
and minor allele frequency of 0.2 for allelic association for
the 1st stage analysis. There were 262 SNPs with P values <
0.002, and among them, 138 SNPs had minor allele fre-
quencies > 0.2. We further chose 125 SNPs that were not
in tightly linked with other SNPs for the 2nd stage analysis.
SNP typing for 2nd and 3rd stages was performed using the
TaqMan Assay-on-Demand™ and Assay-by-Design SNP
Assay Systems (Applied Biosystems, Foster City, CA) as
per the manufacture's instructions. The pedigree disequi-
librium test (PDT) [15] for the family-based association
study (2nd stage) was performed using the UNPHASED
program version 2.404 http://www.mrc-bsu.cam.ac.uk/
personal/frank/software/unphased/. The PDT can use
data from related nuclear families from extended pedi-
grees with multiple offspring and is valid even when there
is population substructure. Eight SNPs (rs1045487,
rs2288601, rs3773265, rs2273188, rs2041125,
rs3213733, rs3771140, and rs2820421) were observed to
be associated with asthma at the significance levels of P <
0.05, however, the risk alleles for asthma in 5 SNPs
(rs1045487, rs2288601, rs3773265, rs2273188, and
rs2041125) differed from the ones observed in the 1st
stage analysis. Therefore, we further genotyped the
remaining 3 SNPs in a larger replication panel comprising
children with atopic asthma and healthy adult controls
without atopic disease (3rd stage). The results of these 3
SNPs are shown in Table 3. Although the SNPs located in
the 5' region of peroxisome biogenesis factor 19 (PEX19,
rs2820421) were significantly associated with P < 0.05
through the 1st to the 3rd stage analyses, the P values did
not reach statistically significant levels (combined, P = 3.8
× 10-5, calculated by the method described by Kirov et al
[16]; statistically significant levels with Bonferroni correc-
tion, P = 6.57 × 10-7).
Our results revealed a few candidate genes of pediatric
asthma. Though the P values did not reach statistically sig-
nificant levels, SNPs in the 5' region of PEX19 were con-
sistently associated with asthma in the 1st to the 3rd stage
analyses. On the contrary, SNPs on hippocalcin-like 1
(HPCAL1, rs3771140) and on interleukin (IL)18R1
(rs3213733) were associated with asthma in the 1st and
2nd stage analyses, but the associations were not observed
in the 3rd stage analysis.
Pairwise linkage disequilibrium (LD) plots using HapMap
data of the Japanese and Chinese population revealed that
Table 2: Study design
Case Control Analysis No of SNPs
1st stage Childhood atopic Asthma: 288 General Japanese population: 1032 χ2 test (allelic) 82,935
2nd stage Family with childhood atopic asthma (216 families, 762 members) PDT 125
3rd stage Childhood atopic Asthma: 541 Non atopic control: 752 χ2 test (allelic) 3
Table 3: Association results of three SNPs
7 1st stage 2nd stage 3rd stage
Gene rs number Allele Case* Control* P value
(Corrected P)
PDT
P value
Case* Control* P value
HPCAL1 rs3771140 A 0.84 0.77 0.0011
(0.0021)
0.0258 0.78 0.78 0.86
PEX19 rs2820421 A 0.55 0.48 0.0013
(0.0025)
0.045 0.53 0.47 0.0306
IL18R1 rs3213733 G 0.89 0.84 0.0019
(0.0035)
0.0246 0.83 0.82 0.62
*Allele frequenciesBMC Research Notes 2009, 2:54 http://www.biomedcentral.com/1756-0500/2/54
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the SNPs were located in a tight LD region, spanning
approximately 150-kb between rs822450 and rs6668576,
and 4 genes (PEA15, WDR42A, PEX19, and COPA) were
located in the LD region (Figure 1).
PEX19 is a human ortholog of the Saccharomyces cerevisiae
gene, Pex19p, which encodes an oleic acid-inducible, far-
nesylated protein essential for peroxisome biogenesis
[17]. Peroxisomes function to rid cells of toxic substances,
such as hydrogen peroxide, or other metabolites and are
essential for human survival. It has been reported that, in
mice cells, Pex19p interacts with p19ARF in the cell cyto-
plasm and excludes p19ARF from the nucleus, leading to
a concurrent inactivation of p53 function [18]. p19ARF is
encoded by the cyclin-dependent kinase inhibitor 2a
(Cdkn2a), and the human ortholog of Cdkn2a
(CDKN2A) has been extensively examined in relation to
cancer and aging [19]. Down regulation of Pex19p by its
antisense expression resulted in increased levels of
p19ARF, increased p53 function, and a p53/p21WAF1-
mediated senescence [18]. p19ARF proteins regulate p53
pathways, and the disruption of these proteins results in
aberrant cell cycle regulation and perturbation of apop-
totic response [20]. Recently, it has been shown that
p19Arf overexpression resulted in impaired transition
from CD4(-)CD8(-) (double negative stage) to
CD4(+)CD8(+) (double positive stage), leading to
impaired thymocyte expansion and development [21].
Functions of other 3 genes, WDR42A, PEA15 and COPA
for the immune systems are currently not well under-
stood.
IL-18 was initially identified as a potent interferon gamma
(IFNγ)-inducing factor, and was later shown to have the
potential to induce IL-4 production. Therefore, IL-18 can
induce both IFNγ and IL-4 responses depending on its
cytokine environment [22]. Recently, polymorphisms in
IL18 receptor 1 (IL18R1) have been reported to be associ-
ated with asthma and bronchial hyperresponsiveness in
the European population [23,24]. Therefore, IL18R1 is a
good candidate for asthma, and further replication studies
are required to determine the causal variants.
In the present study, we did not detect statistically signifi-
cant associations of asthma with SNPs. This may be
because of the limited statistical power, considering the
sample size and extent of multiple testing. Our statistical
power in the 3rd-stage analysis was 95%, but the powers
LD map around rs2820421 Figure 1
LD map around rs2820421. Top, locations of the genes in the 150 kb LD region. Bottom, Haploview plot of LD blocks. Red 
color indicates strong LD, expressed as r2. SNPs with an allele frequency > 0.2 are shown. An arrow indicates the location of 
rs2820421.
WDR42A
PEA15 PEX19
COPA
150 kb
Chr1
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of the 1st- and 2nd-stage analyses were 0.95 and 0.85 with
a genotypic relative risk of 2.0, and 0.41 and 0.45 with a
genotypic relative risk of 1.5, respectively. Another reason
is population stratification in the 1st-stage analysis.
Although we collected the case and control samples from
geographic regions wherein people are considered to be
genetically similar, population stratification may exists in
our case-control samples, leading to the inflated test sta-
tistics.
In summary, we performed a large scale genotyping study
to identify the susceptibility genes for pediatric asthma.
Although no SNPs attained genome-wide significance, we
identified several loci with a possible association with
asthma. Further studies are required to validate these
results for the prevention and treatment of asthma.
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